Compass Therapeutics, Inc. (CMPX)

From a clinical protocol standpoint, tracking the asset expenditures is essential. In our oncology evaluation group, we noted that tovecimig RandD spending climbed to $10.3 million for the quarter ending June 30, 2026, up from $7.7 million the previous year. As we review trial execution in biliary tract cancer (BTC), the allocation toward microvasculature modulation and angiogenesis-targeted agents forms the backbone of their therapeutic strategy. Any prospective investigator or clinical consultant coming onboard must understand how closely management ties its pipeline milestones to this specific capital burn rate.

On our desk, CMPX has caught attention following reports highlighting up to a 130% potential upside and a year-on-year climb, paired with an AI price target averaging around $2.50 to a high of $3.23. With basic and diluted weighted-average shares sitting at roughly 186.8 million—including 6.7 million pre-funded warrants—market sentiment remains surprisingly resilient. The validation of cash runway stretching safely into 2028 via $180 million in liquidity gives macro desks comfort that near-term dilution risk is mitigated despite ongoing quarterly losses.

Watching the option volatility metrics, I see an expected volatility factor hovering around 85% with a 3.86% risk-free rate in their recent filings. As a quantitative risk analyst, the sheer volume of out-of-the-money or anti-dilutive securities—such as the 23.65 million stock options excluded from diluted EPS due to anti-dilution—presents a structural overhang. While the clinical-stage focus on tumor microenvironments is scientifically sound, investors must price in the reality of expanding SGandA costs, which rose to $7.4 million in Q2 2026 alongside wider net losses.